vs

Side-by-side financial comparison of Dexcom (DXCM) and Ryerson Holding Corp (RYI). Click either name above to swap in a different company.

Dexcom is the larger business by last-quarter revenue ($1.3B vs $1.1B, roughly 1.1× Ryerson Holding Corp). Dexcom runs the higher net margin — 21.2% vs -3.4%, a 24.7% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 9.7%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs -5.6%).

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

Joseph T. Ryerson & Son, Inc. is a services company that processes and distributes metals, with operations in the United States, Mexico, Canada, and China. Founded in 1842, Ryerson is headquartered in Chicago and employs approximately 4,200 employees at about 100 locations.

DXCM vs RYI — Head-to-Head

Bigger by revenue
DXCM
DXCM
1.1× larger
DXCM
$1.3B
$1.1B
RYI
Growing faster (revenue YoY)
DXCM
DXCM
+11.9% gap
DXCM
21.6%
9.7%
RYI
Higher net margin
DXCM
DXCM
24.7% more per $
DXCM
21.2%
-3.4%
RYI
Faster 2-yr revenue CAGR
DXCM
DXCM
Annualised
DXCM
12.0%
-5.6%
RYI

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DXCM
DXCM
RYI
RYI
Revenue
$1.3B
$1.1B
Net Profit
$267.3M
$-37.9M
Gross Margin
62.9%
15.3%
Operating Margin
25.6%
-3.4%
Net Margin
21.2%
-3.4%
Revenue YoY
21.6%
9.7%
Net Profit YoY
153.6%
-781.4%
EPS (diluted)
$0.67
$-1.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DXCM
DXCM
RYI
RYI
Q1 26
$1.3B
Q4 25
$1.3B
$1.1B
Q3 25
$1.2B
$1.2B
Q2 25
$1.2B
$1.2B
Q1 25
$1.0B
$1.1B
Q4 24
$1.1B
$1.0B
Q3 24
$994.2M
$1.1B
Q2 24
$1.0B
$1.2B
Net Profit
DXCM
DXCM
RYI
RYI
Q1 26
$267.3M
Q4 25
$267.3M
$-37.9M
Q3 25
$283.8M
$-14.8M
Q2 25
$179.8M
$1.9M
Q1 25
$105.4M
$-5.6M
Q4 24
$151.7M
$-4.3M
Q3 24
$134.6M
$-6.6M
Q2 24
$143.5M
$9.9M
Gross Margin
DXCM
DXCM
RYI
RYI
Q1 26
62.9%
Q4 25
62.9%
15.3%
Q3 25
60.5%
17.2%
Q2 25
59.5%
17.9%
Q1 25
56.9%
18.0%
Q4 24
58.9%
19.0%
Q3 24
59.7%
17.9%
Q2 24
62.4%
18.2%
Operating Margin
DXCM
DXCM
RYI
RYI
Q1 26
25.6%
Q4 25
25.6%
-3.4%
Q3 25
20.1%
-0.1%
Q2 25
18.4%
0.5%
Q1 25
12.9%
0.2%
Q4 24
17.0%
0.3%
Q3 24
15.3%
0.5%
Q2 24
15.7%
1.9%
Net Margin
DXCM
DXCM
RYI
RYI
Q1 26
21.2%
Q4 25
21.2%
-3.4%
Q3 25
23.5%
-1.3%
Q2 25
15.5%
0.2%
Q1 25
10.2%
-0.5%
Q4 24
13.6%
-0.4%
Q3 24
13.5%
-0.6%
Q2 24
14.3%
0.8%
EPS (diluted)
DXCM
DXCM
RYI
RYI
Q1 26
$0.67
Q4 25
$0.67
$-1.18
Q3 25
$0.70
$-0.46
Q2 25
$0.45
$0.06
Q1 25
$0.27
$-0.18
Q4 24
$0.37
$-0.13
Q3 24
$0.34
$-0.20
Q2 24
$0.35
$0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DXCM
DXCM
RYI
RYI
Cash + ST InvestmentsLiquidity on hand
$917.7M
$26.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.7B
$753.1M
Total Assets
$6.3B
$2.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DXCM
DXCM
RYI
RYI
Q1 26
$917.7M
Q4 25
$917.7M
$26.9M
Q3 25
$1.8B
$29.8M
Q2 25
$1.2B
$30.8M
Q1 25
$904.9M
$33.6M
Q4 24
$606.1M
$27.7M
Q3 24
$621.2M
$35.0M
Q2 24
$939.2M
$28.0M
Stockholders' Equity
DXCM
DXCM
RYI
RYI
Q1 26
$2.7B
Q4 25
$2.7B
$753.1M
Q3 25
$2.7B
$787.3M
Q2 25
$2.6B
$811.5M
Q1 25
$2.3B
$803.9M
Q4 24
$2.1B
$815.3M
Q3 24
$2.0B
$832.9M
Q2 24
$2.4B
$877.9M
Total Assets
DXCM
DXCM
RYI
RYI
Q1 26
$6.3B
Q4 25
$6.3B
$2.4B
Q3 25
$7.5B
$2.5B
Q2 25
$7.3B
$2.5B
Q1 25
$6.8B
$2.5B
Q4 24
$6.5B
$2.4B
Q3 24
$6.4B
$2.5B
Q2 24
$6.8B
$2.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DXCM
DXCM
RYI
RYI
Operating Cash FlowLast quarter
$112.7M
Free Cash FlowOCF − Capex
$91.9M
FCF MarginFCF / Revenue
8.3%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$35.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DXCM
DXCM
RYI
RYI
Q1 26
Q4 25
$294.0M
$112.7M
Q3 25
$659.9M
$-8.3M
Q2 25
$303.0M
$23.8M
Q1 25
$183.8M
$-41.2M
Q4 24
$301.4M
$92.2M
Q3 24
$199.5M
$134.6M
Q2 24
$279.4M
$25.9M
Free Cash Flow
DXCM
DXCM
RYI
RYI
Q1 26
Q4 25
$192.1M
$91.9M
Q3 25
$579.4M
$-21.1M
Q2 25
$208.9M
$13.9M
Q1 25
$96.8M
$-49.2M
Q4 24
$176.8M
$68.7M
Q3 24
$88.3M
$103.0M
Q2 24
$213.3M
$3.2M
FCF Margin
DXCM
DXCM
RYI
RYI
Q1 26
Q4 25
15.3%
8.3%
Q3 25
47.9%
-1.8%
Q2 25
18.1%
1.2%
Q1 25
9.3%
-4.3%
Q4 24
15.9%
6.8%
Q3 24
8.9%
9.1%
Q2 24
21.2%
0.3%
Capex Intensity
DXCM
DXCM
RYI
RYI
Q1 26
Q4 25
8.1%
1.9%
Q3 25
6.7%
1.1%
Q2 25
8.1%
0.8%
Q1 25
8.4%
0.7%
Q4 24
11.2%
2.3%
Q3 24
11.2%
2.8%
Q2 24
6.6%
1.9%
Cash Conversion
DXCM
DXCM
RYI
RYI
Q1 26
Q4 25
1.10×
Q3 25
2.33×
Q2 25
1.69×
12.53×
Q1 25
1.74×
Q4 24
1.99×
Q3 24
1.48×
Q2 24
1.95×
2.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DXCM
DXCM

Segment breakdown not available.

RYI
RYI

US$988.3M89%
Non Us$116.5M11%

Related Comparisons